BiogenedWAR:BGD 68 OCF Margin % is 1.62% as of Mar. 2026, which is 84% below its 10-year median of 10.11. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł23.80 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Biogened ranks better than 52.65% on this metric.
The historical rank and industry rank for Biogened's OCF Margin % or its related term are showing as below:
WAR:BGD'
s OCF Margin % Range Over the Past 10 Years
Min: -2.95 Med: 10.11 Max: 18.02
Current: 10.46
During the past 13 years, the highest OCF Margin % of Biogened was 18.02%. The lowest was -2.95%. And the median was 10.11%.
WAR:BGD's OCF Margin % is ranked better than 52.65% of 961
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs WAR:BGD: 10.46
Biogened OCF Margin % Related Terms
Biogened OCF Margin % Historical Data
* Premium members only.
The historical data trend for Biogened's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:BGD vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Biogened's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogened (WAR:BGD) has a OCF Margin % of 1.62% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biogened and its competitors. This is 84% below median its historical median of 10.11. According to the industry distribution chart, Biogened ranks #455 out of 961 companies in the Drug Manufacturers industry, placing it in the top 47.3%.
Is Biogened's OCF Margin % too high?
Biogened's current OCF Margin % of 1.62% is 84% below median its 10-year median of 10.11. The Drug Manufacturers industry median OCF Margin % is 9.94. Biogened's value of 1.62% is 83.7% below this industry median. Based on the distribution chart, Biogened ranks #455 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #455 out of 961 companies for OCF Margin %. This puts Biogened in the upper half of its industry. The industry median OCF Margin % is 9.94. Biogened's value of 1.62% is 83.7% below this benchmark. While the company's 10-year median is 10.11 vs. the industry median of 9.94, Biogened has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current OCF Margin % of 1.62% is 83.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current OCF Margin % is 1.62%, which is 84% below median its own 10-year median of 10.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.80, compared to a current price of zł18.40 — trading 22.7% below its estimated fair value. The current OCF Margin % is 1.62%, which is 84% below median its 10-year median of 10.11 and 83.7% below the Drug Manufacturers industry median of 9.94. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biogened (WAR:BGD), the current OCF Margin % is 1.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł18.40 is trading 22.7% below its estimated GF Value™ of zł23.80.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
OCF Margin %: 1.62% (84% below median its 10-year median of 10.11)
GF Value™: zł23.80 vs. price of zł18.40 (22.7% below fair value)
Industry Position: 83.7% below the Drug Manufacturers median (#455 of 961)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score
Get the complete analysis for WAR:BGD
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 
